Patent assignee · US · COMPANY

Tesaro, Inc.

🏢 View company profile →
18Patents
16Active
18Granted
49Portfolio score

Filing activity: Nov 1, 2017 → Jul 15, 2022

Most-cited patents

PatentTitleAreaCited byStatus
US11155624B2 Antibodies directed against programmed death-1 (PD-1) Chemistry; Metallurgy 2 Active
US11622961B2 Combination therapies for treating cancer Human Necessities 1 Active
US11407830B2 Methods of treating cancer with anti-PD-1 antibodies Chemistry; Metallurgy 1 Active
US11091459B2 Niraparib compositions Chemistry; Metallurgy 1 Active
US11661453B2 Combination therapies for treating cancer with niraparib and PD-1 inhibitors Chemistry; Metallurgy 1 Active
US11926665B2 Methods of treating cancer with anti-TIM-3 antibodies Chemistry; Metallurgy 1 Active
US11161834B2 Methods of manufacturing of niraparib Emerging Cross-Sectional Technologies 1 Active
US11753472B2 Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) Emerging Cross-Sectional Technologies 1 Active
US12297184B2 Niraparib salts Chemistry; Metallurgy 0 Active
US12005057B2 Methods of treating ovarian cancer General 0 Revoked
US11673877B2 Niraparib compositions Chemistry; Metallurgy 0 Active
US10829476B2 Niraparib compositions General 0 Revoked
US11801240B2 Combination therapies and uses thereof Human Necessities 0 Active
US11629137B2 Methods of manufacturing of niraparib Emerging Cross-Sectional Technologies 0 Active
US11730725B2 Niraparib formulations Human Necessities 0 Active
US12415855B2 Methods of treating cancer with anti-PD-1 antibodies Chemistry; Metallurgy 0 Active
US12156872B2 Combination therapies for treating cancer Electricity 0 Active
US12383542B2 Methods of treating ovarian cancer Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.